PHARMAC is aware of only one manufacturer of the active ingredient in cilazapril internationally. Cilazapril is used infrequently or not at all in other countries.
This means if a supply issue were to occur, then it would likely be difficult to resolve or mitigate. This could have a significant impact on patients and health care professionals.
PHARMAC has secured supplies of a new brand of cilazapril tablets (Zapril) until 2022. We cannot guarantee supplies after 2022.
Supply of cilazapril with hydrochlorothiazide has been discontinued and will no longer be available from late 2020.
The supply chain challenges presented by the COVID-19 pandemic have once again shone a light on New Zealand’s over-reliance on cilazapril.
Sept 2020: Potential supply issue with Zapril
We have been made aware of a potential supply issue affecting Zapril brand cilazapril tab 5 mg (Pharmacode 2379090). In order to maintain continuity of supply, we are removing all-at-once dispensing from Zapril tab 5mg from 1 October 2020.
What prescribers can do
When prescribing an ACE inhibitor, consider prescribing a different one than cilazapril.
BPAC has prepared advice comparing the funded ACE inhibitors, including recommended doses.